Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis
Top Cited Papers
- 1 January 2021
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (1) , 139-147
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
- Almirall
- Amgen
- AnaptysBio
- Asana Biosciences
- Boehringer Ingelheim
- Celgene
- Dermavant
- DS Biopharma
- Eli Lilly
- Galderma
- Ichnos Sciences
- Innovaderm
- Janssen
- Kiniska
- Kyowa Kirin
- LEO Pharma
- Novan
- Pfizer
- Ralexar
- Regeneron
- Sienna Biopharma
- UCB
- Union Therapeutics
This publication has 37 references indexed in Scilit:
- Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysisJournal of Dermatological Science, 2018
- Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?British Journal of Dermatology, 2018
- Epidemiology of atopic dermatitis in adults: Results from an international surveyAllergy, 2018
- Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysisInternational Immunopharmacology, 2018
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2017
- Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialThe Lancet, 2016
- Targeting key proximal drivers of type 2 inflammation in diseaseNature Reviews Drug Discovery, 2015
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitisOphthalmology, 2003